Reinventing the fight against bacteria,
one phage at a time.

Personalized bacteriophage therapy has reached an important milestone. On September 21, 2026, Nature Medicine published what its authors describe as the first detailed, consensus-based guideline covering the practical use of personalized phage therapy from the identification of a patient’s bacterial pathogen to phage selection, pharmaceutical preparation, clinical administration, monitoring and long-term follow-up. The document moves beyond general recommendations and attempts to define a workable clinical and pharmaceutical framework for treating difficult bacterial infections when conventional options are insufficient. Figure 1. Overview of the two main approaches to bacteriophage therapy: personalized treatment based on phages matched to an individual patient’s bacterial isolate, and standardized phage products evaluated through clinical trials. The figure also distinguishes phage active pharmaceutical ingredients (APIs) from finished phage therapy medicinal products (PTMPs). Source...

A new Nature Communications study addresses a problem that remains poorly defined in bacteriophage therapy: how much phage should be administered, how often it should be given, and whether systemic or local delivery is preferable when treating an established wound infection. Researchers led by Yung-Hao Lin, Tejas Dharmaraj and Qingquan Chen, with Ovijit Chaudhuri and Paul L. Bollyky jointly supervising the work, developed a murine Pseudomonas aeruginosa wound model specifically designed to compare these variables and then used the results to engineer a sustained-release phage hydrogel called HydroPhage. The study was accepted on September 9, 2026. The work involved researchers from Stanford University and Stanford Medicine together with collaborators from University Hospital Münster, Radboud University, New Jersey Institute of Technology and other institutions. Its experimental focus was not simply whether a bacteriophage could kill P. aeruginosa, but how pharmacological variables suc...

Armata Pharmaceuticals announced on September 14, 2026 that the US Food and Drug Administration has granted Breakthrough Therapy designation to AP-SA02, its intravenously administered fixed bacteriophage cocktail being developed as an adjunct to antibiotics for complicated Staphylococcus aureus bacteremia caused by either methicillin-sensitive S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA). The designation follows positive results from the randomized Phase 1b/2a diSArm study and adds a third major FDA regulatory designation to AP-SA02 after Qualified Infectious Disease Product status in February 2026 and Fast Track designation in May. Illustrative image created by The Phage Therapy. This is not an official photograph from Armata Pharmaceuticals and does not depict actual AP-SA02 commercial packaging. AP-SA02 remains an investigational bacteriophage therapy and is not FDA-approved. The Armata Pharmaceuticals name and logo are used for identification purposes and remain th...

Antimicrobial resistance is progressively reducing the effectiveness of drugs on which modern medicine depends. A CNN investigation published on September 9, 2026 examines the consequences through patients affected by severe infections that became increasingly difficult to treat, while also discussing bacteriophage therapy as an experimental strategy for bacterial infections resistant to conventional antibiotics. The global burden is already substantial. According to the World Health Organization, bacterial antimicrobial resistance was associated with more than 4.7 million deaths worldwide in 2021, including approximately 1.14 million deaths directly attributable to resistance. Current modelling projects around 39 million deaths directly attributable to bacterial AMR cumulatively between 2025 and 2050 if current trends continue, rather than 39 million deaths in a single year. Source :  https://edition.cnn.com/2026/09/09/asia/health-antibiotics-amr-intl-hnk-dst Resistance develops ...

Ami Bhatt’s research at Stanford connects three problems that are usually studied separately: the origin of bloodstream infections in immunocompromised patients, rapid genome evolution in hospital-adapted bacteria, and the use of microbial recombinases to engineer human cells. In a September 2026 episode of Stanford Medicine’s The Future of Medicine , Bhatt described how her group studies microbial communities as evolving genomic systems rather than static lists of bacterial species. The laboratory focuses particularly on mobile genetic elements, including transposable elements and bacteriophages, because these sequences can alter bacterial genomes over clinically relevant timescales. Source of the image :  https://medicine.stanford.edu/news/stories/episodes/ami-bhatt-microbiome-superbugs-cancer-therapy.html One major application is hematopoietic cell transplantation. These patients receive combinations of chemotherapy, immunosuppressive drugs and broad-spectrum antibiotics that c...